Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

June 26, 2026

Study Completion Date

June 26, 2026

Conditions
Advanced NSCLC
Interventions
DRUG

JS207 injection +docetaxel

Patients receive JS207 10mg/kg or other dosage and docetaxel 75mg/m2, q3w.

DRUG

JS207 injection +JS004 injection

Patients receive JS207 10mg/kg or other dosage and JS004 200mg, q3w.

DRUG

JS207 injection

Patients receive JS207 10mg/kg or other dosage.

Trial Locations (26)

101100

RECRUITING

Beijing Chest Hospital, Capital Medical University, Beijing

130012

NOT_YET_RECRUITING

Jilin Cancer Hospital, Jilin

150081

RECRUITING

Harbin Medical University Cancer Hospital, Heilongjiang

200030

NOT_YET_RECRUITING

Shanghai Chest Hospital, Shanghai

200433

NOT_YET_RECRUITING

Shanghai Pulmonary Hospital, Shanghai

NOT_YET_RECRUITING

Shanghai Pulmonary Hospital, Shanghai

310022

NOT_YET_RECRUITING

Zhejiang Cancer Hospital, Zhejiang

325000

NOT_YET_RECRUITING

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

330000

RECRUITING

The First Affiliated Hospital of Nanchang University, Jiangxi

350005

NOT_YET_RECRUITING

The First Affiliated Hospital of Fujian Medical University, Fuzhou

400037

RECRUITING

Second Affiliated Hospital, PLA Academy of Military Medical Sciences, Chongqing

400042

RECRUITING

Army Medical Center, PLA, Chongqing

410031

RECRUITING

Hunan Cancer Hospital, Hunan

415003

RECRUITING

The First People's Hospital of Changde, Changde

453100

NOT_YET_RECRUITING

The First Affiliated Hospital of Xinxiang Medical University, Xinxiang

455000

RECRUITING

Anyang Tumor Hospital, Anyang

471003

NOT_YET_RECRUITING

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

510120

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangdong

514031

NOT_YET_RECRUITING

Meizhou People's Hospital, Meizhou

515031

NOT_YET_RECRUITING

Shantou University Medical College Affiliated Cancer Hospital, Shantou

523000

NOT_YET_RECRUITING

Department of Medical Oncology, Dongguan

610044

RECRUITING

West China Hospital, Sichuan University, Sichuan

644000

NOT_YET_RECRUITING

Yibin Second People's Hospital, Yibin

830011

NOT_YET_RECRUITING

Affiliated Tumor Hospital of Xinjiang Medical University, Xinjiang

Unknown

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

037008

RECRUITING

The Third People's Hospital of Datong, Datong

All Listed Sponsors
lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER

NCT06924606 - Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy | Biotech Hunter | Biotech Hunter